Allianz Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Allianz Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,900	Closed	-$387K	–	2191
2025 Q1	$387K	Hold	9,900	–	–	﹤0.01%	1958
2024 Q4	$536K	Buy	9,900 +4,700	+90%	+$240K	﹤0.01%	1843
2024 Q3	$262K	Sell	5,200 -7,100	-58%	-$333K	﹤0.01%	2022
2024 Q2	$541K	Hold	12,300	–	–	﹤0.01%	1809
2024 Q1	$618K	Hold	12,300	–	–	﹤0.01%	1551
2023 Q4	$743K	Buy	12,300 +4,200	+52%	+$216K	﹤0.01%	1723
2023 Q3	$462K	Buy	8,100 +3,700	+84%	+$204K	﹤0.01%	1947
2023 Q2	$224	Buy	+4,400	New	+$118K	﹤0.01%	2116

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Allianz Asset Management's MLTX Position: Q2 2025 in Review

Allianz Asset Management sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2025, closing a stake of 9,900 shares — an estimated $387K sold.

Allianz Asset Management first reported a position in MLTX in Q2 2023 and held it in 8 quarters. The position peaked at $743K in Q4 2023. 130 funds tracked by Wall St. Rank hold MLTX as of Q2 2025.

Allianz Asset Management reported no remaining MoonLake Immunotherapeutics position as of Q2 2025 after selling out during the quarter.
Allianz Asset Management sold 9,900 MoonLake Immunotherapeutics shares in Q2 2025, an estimated $387K.
Allianz Asset Management first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 8 quarters.
Allianz Asset Management's MoonLake Immunotherapeutics position peaked at $743K in Q4 2023.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2025.

Based on Allianz Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.